NCT01658449

Comparison of the Tolerability of Two Formulations of Hypertonic Saline in Cystic Fibrosis Patients

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Ospedale Civile Ca' Foncello · Academic / Other
• Sex: All
• Age: 8 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to compare the tolerability and acceptability of a formulation containing Hypertonic saline 7% (HS) alone and a formulation containing HS and Hyaluronic acid 0.1% in a population of Cystic Fibrosis (CF) patients who already showed poor tolerance to HS.

Conditions

• Cystic Fibrosis

Interventions

Type	Name	Description
OTHER	Inhalable Hypertonic saline 7% + Hyaluronan 0.1%	Administration of Inhalable Hypertonic saline 7% + Hyaluronan 0.1% 5 ml twice a day, after bronchodilator for one month.
OTHER	Inhalable Hypertonic saline 7%	Administration of Inhalable Hypertonic saline 7% 5 ml twice a day, after bronchodilator for one month.

Timeline

• Start date: 2009-12-01
• Primary completion: 2011-06-01
• Completion: 2011-09-01
• First posted: 2012-08-07
• Last updated: 2012-08-10

Locations

1 site across 1 country: Italy